Process Development in the Synthesis of the ACE Intermediate MDL 28,726

MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Organic process research & development 1999, Vol.3 (4), p.241-247
Hauptverfasser: Horgan, Stephen W, Burkhouse, David W, Cregge, Robert J, Freund, David W, LeTourneau, Michael, Margolin, Alexey, Webster, Mark E, Henton, Daniel R, Barton, Kathy P, Clouse, Robert C, DesJardin, Michael A, Donaldson, Richard E, Fetner, Neal J, Goralski, Christian T, Heinrich, Gerald P, Hoops, John F, Keaten, Robert T, McConnell, J. Russell, Nitz, Mark A, Stolz-Dunn, Sandra K
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 247
container_issue 4
container_start_page 241
container_title Organic process research & development
container_volume 3
creator Horgan, Stephen W
Burkhouse, David W
Cregge, Robert J
Freund, David W
LeTourneau, Michael
Margolin, Alexey
Webster, Mark E
Henton, Daniel R
Barton, Kathy P
Clouse, Robert C
DesJardin, Michael A
Donaldson, Richard E
Fetner, Neal J
Goralski, Christian T
Heinrich, Gerald P
Hoops, John F
Keaten, Robert T
McConnell, J. Russell
Nitz, Mark A
Stolz-Dunn, Sandra K
description MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the N-trifluoroacetamide of (R,S)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.
doi_str_mv 10.1021/op970125x
format Article
fullrecord <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_op970125x</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>e66588139</sourcerecordid><originalsourceid>FETCH-LOGICAL-a209t-2b6872685f91efb3ae6e39c18ca8b347e9956e57ac330dec1659450bfedd9273</originalsourceid><addsrcrecordid>eNptkE1LAzEYhIMoWKsH_0EuHgRX3yRNNjmWba2FFQV78LZks29wS_eDZBX7712tePI0w_AwDEPIJYNbBpzddb1JgXH5eUQmTHJIpFavx6MHLRLFFJySsxi3ACAV4xOyeg6dwxjpAj9w1_UNtgOtWzq8IX3Zt6PEOtLO_wTzbEnX7YChwaq2A9LHRU65vkm5Oicn3u4iXvzqlGzul5vsIcmfVutsnieWgxkSXio90lp6w9CXwqJCYRzTzupSzFI0RiqUqXVCQIWOKWlmEkqPVWV4Kqbk-lDrQhdjQF_0oW5s2BcMiu8Dir8DRvbqwFoXi233Htpx2D_cF5WBWFE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Process Development in the Synthesis of the ACE Intermediate MDL 28,726</title><source>ACS Publications</source><creator>Horgan, Stephen W ; Burkhouse, David W ; Cregge, Robert J ; Freund, David W ; LeTourneau, Michael ; Margolin, Alexey ; Webster, Mark E ; Henton, Daniel R ; Barton, Kathy P ; Clouse, Robert C ; DesJardin, Michael A ; Donaldson, Richard E ; Fetner, Neal J ; Goralski, Christian T ; Heinrich, Gerald P ; Hoops, John F ; Keaten, Robert T ; McConnell, J. Russell ; Nitz, Mark A ; Stolz-Dunn, Sandra K</creator><creatorcontrib>Horgan, Stephen W ; Burkhouse, David W ; Cregge, Robert J ; Freund, David W ; LeTourneau, Michael ; Margolin, Alexey ; Webster, Mark E ; Henton, Daniel R ; Barton, Kathy P ; Clouse, Robert C ; DesJardin, Michael A ; Donaldson, Richard E ; Fetner, Neal J ; Goralski, Christian T ; Heinrich, Gerald P ; Hoops, John F ; Keaten, Robert T ; McConnell, J. Russell ; Nitz, Mark A ; Stolz-Dunn, Sandra K</creatorcontrib><description>MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the N-trifluoroacetamide of (R,S)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.</description><identifier>ISSN: 1083-6160</identifier><identifier>EISSN: 1520-586X</identifier><identifier>DOI: 10.1021/op970125x</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Organic process research &amp; development, 1999, Vol.3 (4), p.241-247</ispartof><rights>Copyright © 1999 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a209t-2b6872685f91efb3ae6e39c18ca8b347e9956e57ac330dec1659450bfedd9273</citedby><cites>FETCH-LOGICAL-a209t-2b6872685f91efb3ae6e39c18ca8b347e9956e57ac330dec1659450bfedd9273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/op970125x$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/op970125x$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,4010,27053,27900,27901,27902,56713,56763</link.rule.ids></links><search><creatorcontrib>Horgan, Stephen W</creatorcontrib><creatorcontrib>Burkhouse, David W</creatorcontrib><creatorcontrib>Cregge, Robert J</creatorcontrib><creatorcontrib>Freund, David W</creatorcontrib><creatorcontrib>LeTourneau, Michael</creatorcontrib><creatorcontrib>Margolin, Alexey</creatorcontrib><creatorcontrib>Webster, Mark E</creatorcontrib><creatorcontrib>Henton, Daniel R</creatorcontrib><creatorcontrib>Barton, Kathy P</creatorcontrib><creatorcontrib>Clouse, Robert C</creatorcontrib><creatorcontrib>DesJardin, Michael A</creatorcontrib><creatorcontrib>Donaldson, Richard E</creatorcontrib><creatorcontrib>Fetner, Neal J</creatorcontrib><creatorcontrib>Goralski, Christian T</creatorcontrib><creatorcontrib>Heinrich, Gerald P</creatorcontrib><creatorcontrib>Hoops, John F</creatorcontrib><creatorcontrib>Keaten, Robert T</creatorcontrib><creatorcontrib>McConnell, J. Russell</creatorcontrib><creatorcontrib>Nitz, Mark A</creatorcontrib><creatorcontrib>Stolz-Dunn, Sandra K</creatorcontrib><title>Process Development in the Synthesis of the ACE Intermediate MDL 28,726</title><title>Organic process research &amp; development</title><addtitle>Org. Process Res. Dev</addtitle><description>MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the N-trifluoroacetamide of (R,S)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.</description><issn>1083-6160</issn><issn>1520-586X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNptkE1LAzEYhIMoWKsH_0EuHgRX3yRNNjmWba2FFQV78LZks29wS_eDZBX7712tePI0w_AwDEPIJYNbBpzddb1JgXH5eUQmTHJIpFavx6MHLRLFFJySsxi3ACAV4xOyeg6dwxjpAj9w1_UNtgOtWzq8IX3Zt6PEOtLO_wTzbEnX7YChwaq2A9LHRU65vkm5Oicn3u4iXvzqlGzul5vsIcmfVutsnieWgxkSXio90lp6w9CXwqJCYRzTzupSzFI0RiqUqXVCQIWOKWlmEkqPVWV4Kqbk-lDrQhdjQF_0oW5s2BcMiu8Dir8DRvbqwFoXi233Htpx2D_cF5WBWFE</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Horgan, Stephen W</creator><creator>Burkhouse, David W</creator><creator>Cregge, Robert J</creator><creator>Freund, David W</creator><creator>LeTourneau, Michael</creator><creator>Margolin, Alexey</creator><creator>Webster, Mark E</creator><creator>Henton, Daniel R</creator><creator>Barton, Kathy P</creator><creator>Clouse, Robert C</creator><creator>DesJardin, Michael A</creator><creator>Donaldson, Richard E</creator><creator>Fetner, Neal J</creator><creator>Goralski, Christian T</creator><creator>Heinrich, Gerald P</creator><creator>Hoops, John F</creator><creator>Keaten, Robert T</creator><creator>McConnell, J. Russell</creator><creator>Nitz, Mark A</creator><creator>Stolz-Dunn, Sandra K</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1999</creationdate><title>Process Development in the Synthesis of the ACE Intermediate MDL 28,726</title><author>Horgan, Stephen W ; Burkhouse, David W ; Cregge, Robert J ; Freund, David W ; LeTourneau, Michael ; Margolin, Alexey ; Webster, Mark E ; Henton, Daniel R ; Barton, Kathy P ; Clouse, Robert C ; DesJardin, Michael A ; Donaldson, Richard E ; Fetner, Neal J ; Goralski, Christian T ; Heinrich, Gerald P ; Hoops, John F ; Keaten, Robert T ; McConnell, J. Russell ; Nitz, Mark A ; Stolz-Dunn, Sandra K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a209t-2b6872685f91efb3ae6e39c18ca8b347e9956e57ac330dec1659450bfedd9273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horgan, Stephen W</creatorcontrib><creatorcontrib>Burkhouse, David W</creatorcontrib><creatorcontrib>Cregge, Robert J</creatorcontrib><creatorcontrib>Freund, David W</creatorcontrib><creatorcontrib>LeTourneau, Michael</creatorcontrib><creatorcontrib>Margolin, Alexey</creatorcontrib><creatorcontrib>Webster, Mark E</creatorcontrib><creatorcontrib>Henton, Daniel R</creatorcontrib><creatorcontrib>Barton, Kathy P</creatorcontrib><creatorcontrib>Clouse, Robert C</creatorcontrib><creatorcontrib>DesJardin, Michael A</creatorcontrib><creatorcontrib>Donaldson, Richard E</creatorcontrib><creatorcontrib>Fetner, Neal J</creatorcontrib><creatorcontrib>Goralski, Christian T</creatorcontrib><creatorcontrib>Heinrich, Gerald P</creatorcontrib><creatorcontrib>Hoops, John F</creatorcontrib><creatorcontrib>Keaten, Robert T</creatorcontrib><creatorcontrib>McConnell, J. Russell</creatorcontrib><creatorcontrib>Nitz, Mark A</creatorcontrib><creatorcontrib>Stolz-Dunn, Sandra K</creatorcontrib><collection>CrossRef</collection><jtitle>Organic process research &amp; development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horgan, Stephen W</au><au>Burkhouse, David W</au><au>Cregge, Robert J</au><au>Freund, David W</au><au>LeTourneau, Michael</au><au>Margolin, Alexey</au><au>Webster, Mark E</au><au>Henton, Daniel R</au><au>Barton, Kathy P</au><au>Clouse, Robert C</au><au>DesJardin, Michael A</au><au>Donaldson, Richard E</au><au>Fetner, Neal J</au><au>Goralski, Christian T</au><au>Heinrich, Gerald P</au><au>Hoops, John F</au><au>Keaten, Robert T</au><au>McConnell, J. Russell</au><au>Nitz, Mark A</au><au>Stolz-Dunn, Sandra K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Process Development in the Synthesis of the ACE Intermediate MDL 28,726</atitle><jtitle>Organic process research &amp; development</jtitle><addtitle>Org. Process Res. Dev</addtitle><date>1999</date><risdate>1999</risdate><volume>3</volume><issue>4</issue><spage>241</spage><epage>247</epage><pages>241-247</pages><issn>1083-6160</issn><eissn>1520-586X</eissn><abstract>MDL 28,726 is a key intermediate in the synthesis of the ACE inhibitors MDL 27,210A and MDL 100,240. An efficient nine-step synthesis of this tricyclic acid, which has three chiral centers, was developed beginning with 3,4-dihydro-2H-pyran. A key step in the synthesis features an enzyme-catalyzed resolution of the lithium salt of the N-trifluoroacetamide of (R,S)-6-hydroxynorleucine. All of the steps were optimized and completed in reactor equipment using environmentally acceptable processes. Process development of this route is described.</abstract><pub>American Chemical Society</pub><doi>10.1021/op970125x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1083-6160
ispartof Organic process research & development, 1999, Vol.3 (4), p.241-247
issn 1083-6160
1520-586X
language eng
recordid cdi_crossref_primary_10_1021_op970125x
source ACS Publications
title Process Development in the Synthesis of the ACE Intermediate MDL 28,726
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A49%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Process%20Development%20in%20the%20Synthesis%20of%20the%20ACE%20Intermediate%20MDL%2028,726&rft.jtitle=Organic%20process%20research%20&%20development&rft.au=Horgan,%20Stephen%20W&rft.date=1999&rft.volume=3&rft.issue=4&rft.spage=241&rft.epage=247&rft.pages=241-247&rft.issn=1083-6160&rft.eissn=1520-586X&rft_id=info:doi/10.1021/op970125x&rft_dat=%3Cacs_cross%3Ee66588139%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true